ArticleScience immunology2024
TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy.
Abstract read
In one paragraph
Article in Science immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- The impact of gut microbiota and metabolite-driven immune cell spatiotemporal dynamics on tumors.Gut microbes · 2026Review
- PD-1 blockade promotes mucosal CD4+ T cell IL-10 production through altering microbiota to reduce intestinal ischemia reperfusion injury.Gut microbes · 2026Article
- Context-dependent TREM2 signalling in myeloid cells: Molecular mechanisms and immunotherapeutic divergence in neurodegeneration and cancer.Clinical and translational medicine · 2026Review
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer.Nature communications · 2026Article
- TREM2 plays a critical role in innate immune defense against acute Toxoplasma gondii infection by promoting macrophage antimicrobial activities.PLoS pathogens · 2026Article
- Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung Cancer.Research square · 2026Article
- Discovery of a non-canonical TREM2-S100A9 axis that drives pro-tumorigenic macrophage polarization and sensitizes ovarian clear cell carcinoma to IL-17 blockade.Cell death discovery · 2026Article
- The Microglial Protein sTREM2 Inhibits the Bacterial Functional Amyloid CsgA and Suppresses Amyloid-Dependent Biofilm Formation.bioRxiv : the preprint server for biology · 2026Article
- A Microbial Lipid-ATP Synthase Axis Fuels NK Cell Antitumor Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.Cellular & molecular biology letters · 2026Review
- Obesity and Cancer: From Systemic Metabolic Reprogramming to Immunotherapy Paradox.Metabolites · 2026Review
- Immune dysfunction in Alzheimer disease.Nature reviews. Neuroscience · 2026Review
- Gut dysbiosis in oncology: a risk factor for immunoresistance.Cell research · 2026Review
- Review
- Multiomics identifies a cholesterol-TFEB-PLD3-TLR9 axis driving immunosuppressive tumor-associated macrophage polarization in esophageal squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The role of immune cell crosstalk and signaling pathways in the pathogenesis of pulmonary fibrosis.Molecular biology reports · 2026Review
- Parkinson's disease: spatiotemporal regulation and therapeutic prospects of TREM2-mediated microglial responses.NPJ Parkinson's disease · 2026Review
- TREM2: A Potential Target for the Targeted Therapy of Metabolic Diseases.Mediators of inflammation · 2026Review
- Revisiting TREM2: from multi-omics signaling networks to clinical translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Blanda Di LucciaDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0002-0137-953X
Martina MolgoraDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0001-7328-2844
Darya KhantakovaDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0002-2579-5140
Natalia JaegerDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0003-2875-8297
Hao-Wei ChangDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0002-1160-7452
Rafael S CzepielewskiDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0002-2475-3838
Beth A HelminkDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-8206-0351
Emily J OnuferDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-8802-5346
José L FachiDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0002-1035-5193
Bishan BhattaraiDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.
Tihana TrsanDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0002-7549-2885
Patrick F RodriguesDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0002-0214-0627
JinChao HouDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0003-3829-7551
Jennifer K BandoDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0002-1331-7424
Cristiane Sécca da SilvaDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0003-4433-8962
Marina CellaDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0003-1230-1313
Susan GilfillanDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0003-1672-0996
Robert D SchreiberDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0001-6311-0432
Jeffrey I GordonDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0001-8304-3548
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO 63110, USA.ORCID 0000-0001-5222-4987
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MWashington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Brian N Finck · 1999 to 2026
$30.2MREGULATION OF GENE EXPRESSION - SMALL INTESTINER01DK030292 · NIDDK · WASHINGTON UNIVERSITY · PI JEFFREY I GORDON, ANDREI L OSTERMAN · 1986 to 2026
$6.5MLymphatic remodeling and transport of dietary fats in short gut syndromeR01DK119147 · NIDDK · WASHINGTON UNIVERSITY · PI Bahaa Elgendy, Ajay K. Jain · 2019 to 2026
$4.0MTargeting TREM2 to boost anti-cancer therapyR01CA262684 · NCI · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2021 to 2025
$2.1MImmune Checkpoints for Intestinal Innate Lymphoid CellsR00DK118110 · NIDDK · STANFORD UNIVERSITY · PI BANDO, JENNIFER KAORU · 2021 to 2023
$747kNCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA262684NIDDK NIH HHS P30 DK056341NIDDK NIH HHS R00 DK118110NIDDK NIH HHS R01 DK030292NIDDK NIH HHS R01 DK119147
Abstract
The gut microbiota and tumor-associated macrophages (TAMs) affect tumor responses to anti-programmed cell death protein 1 (PD-1) immune checkpoint blockade. Reprogramming TAM by either blocking or deleting the macrophage receptor triggering receptor on myeloid cells 2 (TREM2) attenuates tumor growth, and lack of functional TREM2 enhances tumor elimination by anti-PD-1. Here, we found that anti-PD-1 treatment combined with TREM2 deficiency in mice induces proinflammatory programs in intestinal macrophages and a concomitant expansion of
Indexed as
Gastrointestinal MicrobiomeImmunotherapyMacrophagesMembrane GlycoproteinsMice, Inbred C57BLProgrammed Cell Death 1 ReceptorReceptors, ImmunologicAnimalsImmune Checkpoint InhibitorsIntestinesMiceMice, KnockoutImmune Checkpoint InhibitorsMembrane GlycoproteinsPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTrem2 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.